Global Immuno-oncology Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Treatment Type;
Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Oncolytic Virus.By Distribution Channel;
Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.By Drug Type;
Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy.By Cancer Type;
Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Immuno-oncology Drugs Market (USD Million), 2021 - 2031
In the year 2024, the Global Immuno-oncology Drugs Market was valued at USD 19,306.48 million. The size of this market is expected to increase to USD 43,786.24 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.4%.
The global immuno-oncology drugs market represents a groundbreaking frontier in cancer treatment, leveraging the body's own immune system to combat cancer cells. Immuno-oncology drugs, also known as cancer immunotherapy, have transformed the landscape of cancer care by offering novel therapeutic approaches that harness the power of the immune system to recognize and eradicate tumors.
Global immuno-oncology drugs market is witnessing rapid growth driven by several factors, including increasing cancer prevalence, growing awareness of immunotherapy's potential, and ongoing advancements in biotechnology and cancer research. With an expanding portfolio of approved drugs and promising candidates in clinical development, the immuno-oncology market offers new hope for patients with a wide range of cancers, including melanoma, lung cancer, bladder cancer, and hematological malignancies.
Immuno-oncology field continues to evolve and mature, the global market is poised for further expansion, fueled by ongoing research efforts, strategic collaborations, and regulatory approvals. Immuno-oncology drugs represent a paradigm shift in cancer treatment, offering personalized and potentially curative therapies that target cancer cells while sparing healthy tissues. With continued innovation and investment, immuno-oncology drugs are expected to play an increasingly prominent role in the future of cancer care, driving improvements in patient outcomes and transforming the standard of care for cancer patients worldwide.
Global Immuno-oncology Drugs Market Recent Developments
-
In February 2024, researchers at the University of Florida Health Cancer Center developed a groundbreaking compound that shows potential in enhancing immunotherapy for various cancers. In laboratory and mouse trials focused on skin and colorectal cancer models, the compound effectively slowed tumor growth by stimulating the immune system to target cancer cells, and in some instances, it completely eliminated tumors.
-
In December 2023, GSK plc, a multinational pharmaceutical and biotechnology company, announced that the European Commission (EC) granted marketing authorization for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy. This approval is aimed at treating adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer who require systemic therapy.
Segment Analysis
The Global Immuno-oncology Drugs Market is comprehensively analyzed through segmentation across Treatment Type, Distribution Channel, Drug Type, Cancer Type, and Geography. These dimensions enable a detailed understanding of market dynamics, highlighting the varied approaches and applications driving growth in this innovative sector.
By Treatment Type, the market is categorized into Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Oncolytic Virus Therapies. Among these, checkpoint inhibitors dominate due to their proven efficacy and widespread adoption for treating multiple cancer types. Oncolytic virus therapies and cancer vaccines, though relatively nascent, are poised for growth due to advancements in research and growing interest in personalized medicine.
Segmentation by Distribution Channel includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, reflecting the evolution of drug accessibility and delivery. Hospital pharmacies account for the majority of sales, driven by the need for expert administration of complex therapies. Retail and online pharmacies are expanding, particularly as oral immuno-oncology drugs become more prevalent, offering convenience to patients requiring long-term care.
The market is further segmented by Drug Type, encompassing biologics and small molecule therapies, and by Cancer Type, targeting indications such as lung, melanoma, colorectal, and breast cancers. Geographically, regions like North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa display diverse market dynamics based on healthcare infrastructure, R&D investment, and patient demographics. Together, these segments provide a holistic view of the market’s progression, emphasizing innovation and accessibility.
Global Immuno-oncology Drugs Segment Analysis
In this report, the Global Immuno-oncology Drugs Market has been segmented by Treatment Type, Distribution Channel, Drug Type, Cancer Type, and Geography.
Global Immuno-oncology Drugs Market, Segmentation by Treatment Type
The Global Immuno-oncology Drugs Market has been segmented by Treatment Type into Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines and Oncolytic Virus.
The Global Immuno-oncology Drugs Market is segmented into four primary treatment types: Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Oncolytic Virus Therapies. These categories represent the diverse approaches to leveraging the immune system in combating cancer. Each segment has distinct mechanisms of action, applications, and market dynamics, reflecting the evolving landscape of cancer therapeutics.
Immune Checkpoint Inhibitors are the leading segment, driven by their ability to block proteins that prevent T-cells from attacking cancer cells effectively. Drugs like PD-1/PD-L1 inhibitors (e.g., pembrolizumab and nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab) have demonstrated significant success in treating various cancers, including melanoma, lung cancer, and renal cell carcinoma. This segment benefits from substantial clinical trials, regulatory approvals, and a growing number of combination therapy applications.
Immune System Modulators enhance the overall immune response against tumors by amplifying innate and adaptive immunity. These include cytokines like interleukins and interferons, as well as monoclonal antibodies that stimulate immune activity. Meanwhile, Cancer Vaccines focus on educating the immune system to recognize and attack tumor-associated antigens. Though in an early phase compared to checkpoint inhibitors, their development is gaining traction. Oncolytic Viruses represent a novel category where genetically modified viruses selectively infect and kill cancer cells, often stimulating an anti-tumor immune response. While still emerging, these therapies hold potential for synergy with other immuno-oncology approaches. Together, these segments underline the market's dynamic growth, driven by innovation and unmet clinical needs.
Global Immuno-oncology Drugs Market, Segmentation by Distribution Channel
The Global Immuno-oncology Drugs Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
The Global Immuno-oncology Drugs Market is segmented by distribution channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. This segmentation highlights the various avenues through which these innovative therapies reach patients, addressing the diverse needs of healthcare providers and consumers.
Hospital Pharmacies represent the largest segment due to the complex nature of immuno-oncology treatments, which often require administration under medical supervision. These therapies, such as intravenous immune checkpoint inhibitors or oncolytic virus therapies, necessitate specialized handling, storage, and dosing expertise available in hospital settings. Furthermore, hospitals often serve as the primary point of care for patients undergoing advanced cancer treatments, driving demand through this channel.
Retail Pharmacies and Online Pharmacies are gaining significance as immuno-oncology drugs are increasingly developed in oral formulations, enabling outpatient treatment. Retail pharmacies offer convenience and accessibility for patients requiring continuous therapy, especially for immune system modulators and some cancer vaccines. Meanwhile, Online Pharmacies are witnessing growth due to the rise of digital health services, remote consultations, and e-commerce trends. This channel provides a discreet and efficient option for patients managing long-term treatments, particularly in regions with advanced healthcare infrastructure. Together, these distribution channels ensure widespread access to immuno-oncology drugs, catering to varied patient preferences and care settings.
Global Immuno-oncology Drugs Market, Segmentation by Drug Type
The Global Immuno-oncology Drugs Market has been segmented by Drug Type into Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy.
Immuno-oncology drugs market is immune checkpoint inhibitors, which have revolutionized cancer treatment by blocking inhibitory pathways in the immune system, thereby unleashing antitumor immune responses. Immune checkpoint inhibitors target proteins such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which are involved in regulating T cell activation and immune tolerance. Key drugs in this segment include pembrolizumab, nivolumab, atezolizumab, ipilimumab, and others, which have demonstrated efficacy across a range of cancer types, including melanoma, lung cancer, bladder cancer, and renal cell carcinoma. Monoclonal antibodies, which represent a diverse class of biologic agents designed to target specific antigens expressed on cancer cells or immune cells. Monoclonal antibodies can function as immune checkpoint inhibitors, tumor-targeting antibodies, or immune modulators, depending on their mechanism of action and intended therapeutic use. Examples of monoclonal antibodies include rituximab, trastuzumab, cetuximab, and bevacizumab, which are approved for the treatment of various cancers, including lymphoma, breast cancer, colorectal cancer, and lung cancer.
Cytokine-based immunotherapy constitutes another important segment in the immuno-oncology drugs market, involving the administration of recombinant cytokines such as interleukins (e.g., interleukin-2, interleukin-12) and interferons to modulate immune responses and enhance antitumor activity. These cytokines stimulate immune cells, promote T cell activation and proliferation, and enhance natural killer cell-mediated cytotoxicity against cancer cells. While cytokine therapies have shown efficacy in certain cancers, their use is often limited by significant toxicity and side effects, necessitating careful patient selection and management.
Drugs market includes segments such as cancer vaccines and chimeric antigen receptor (CAR) T-cell therapy, which offer innovative approaches to cancer immunotherapy. Cancer vaccines stimulate the immune system to recognize and attack tumor cells by presenting tumor-specific antigens or peptides, while CAR-T cell therapy involves the genetic modification of patients' T cells to express chimeric antigen receptors targeting specific antigens on cancer cells. These therapies have demonstrated remarkable success in hematological malignancies such as leukemia and lymphoma, paving the way for the development of personalized and targeted immunotherapies for cancer treatment.
Global Immuno-oncology Drugs Market, Segmentation by Cancer Type
The Global Immuno-oncology Drugs Market has been segmented by Cancer Type into Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma , Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers.
Non-small cell lung cancer (NSCLC) stands out as one of the most prevalent and clinically significant cancer types, representing a substantial portion of the immuno-oncology drugs market. Immunotherapy has transformed the treatment landscape for NSCLC, with immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab demonstrating efficacy in both first-line and advanced settings, particularly in patients with programmed death-ligand 1 (PD-L1) expression. Acute myeloid leukemia (AML) and lymphoma represent hematological malignancies where immunotherapy is increasingly being investigated as a treatment option. While traditional chemotherapy remains a cornerstone of AML treatment, novel immunotherapies such as monoclonal antibodies, adoptive cell therapies, and immune checkpoint inhibitors hold promise for improving outcomes in patients with relapsed or refractory disease.
Multiple myeloma, a plasma cell malignancy, is another cancer type targeted by immuno-oncology drugs. Monoclonal antibodies such as daratumumab and elotuzumab, as well as chimeric antigen receptor (CAR) T-cell therapies, have demonstrated efficacy in patients with relapsed or refractory multiple myeloma, offering new treatment options for this challenging disease.
Breast cancer, ovarian cancer, prostate cancer, and colorectal cancer represent common solid tumors where immuno-oncology therapies are being explored as part of combination regimens or targeted approaches. Immune checkpoint inhibitors, cancer vaccines, and CAR-T cell therapies are among the immunomodulatory agents under investigation in these cancer types, with the aim of improving treatment responses and patient outcomes.
Gastric cancers, glioblastoma, and head and neck cancers present additional opportunities for immuno-oncology drug development, with ongoing research focused on identifying novel targets, biomarkers, and combination strategies to overcome treatment resistance and improve survival rates in these aggressive malignancies.
Global Immuno-oncology Drugs Market, Segmentation by Geography
In this report, the Global Immuno-oncology Drugs Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Immuno-oncology Drugs Market Share (%), by Geographical Region, 2024
North America has emerged as a dominant player in the immuno-oncology drugs market, holding a significant share due to factors such as a strong healthcare infrastructure, advanced research and development capabilities, and favorable regulatory environment. The region is home to several key pharmaceutical companies and academic institutions leading the development of immuno-oncology therapies, driving innovation and investment in cancer immunotherapy. Additionally, high healthcare expenditure, increasing cancer prevalence, and growing adoption of novel immunotherapies contribute to North America's prominent position in the global immuno-oncology drugs market.
Europe represents another important market for immuno-oncology drugs, with a substantial share attributed to its large patient population, well-established healthcare systems, and supportive regulatory framework. Countries such as the United Kingdom, Germany, France, and Switzerland are at the forefront of immuno-oncology research and development, hosting leading biopharmaceutical companies and academic centers engaged in cancer immunotherapy. The European market benefits from robust clinical trial infrastructure, collaborative research networks, and government initiatives aimed at advancing cancer care and accelerating drug approvals. Moreover, increasing awareness of the benefits of immunotherapy, along with reimbursement policies and access to innovative treatments, contributes to the growth of the immuno-oncology drugs market in Europe.
Asia-Pacific is witnessing rapid growth in the immuno-oncology drugs market, fueled by factors such as rising cancer incidence, expanding healthcare infrastructure, and growing investment in biopharmaceutical research and development. Countries like China, Japan, and South Korea are key players in the region, with a burgeoning biotechnology sector and increasing focus on precision medicine and personalized cancer care. The Asia-Pacific market benefits from a large patient pool, diverse genetic backgrounds, and collaborations between academic institutions, government agencies, and industry stakeholders to advance cancer immunotherapy research and innovation. Additionally, initiatives to improve healthcare access, enhance regulatory frameworks, and promote clinical trial participation contribute to the region's growing prominence in the global immuno-oncology drugs market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Immuno-oncology Drugs Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Growing Incidence of Cancer
- Advancements in Immunotherapy
- Rising Demand for Targeted Therapies
-
Expansion of Indications for Immuno-oncology Drugs - The expansion of indications for immuno-oncology drugs represents a significant opportunity in the field of cancer treatment, offering new therapeutic options for a broader range of cancer types and patient populations. Immuno-oncology drugs, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines, harness the power of the immune system to recognize and destroy cancer cells. As our understanding of the immune system and its role in cancer continues to evolve, researchers are exploring novel approaches to expand the use of immuno-oncology drugs beyond traditional indications, such as melanoma and lung cancer, to include a diverse array of tumor types.
Advances in biomarker discovery and patient stratification have facilitated the identification of subpopulations of cancer patients who are most likely to benefit from immuno-oncology drugs. Biomarkers, such as programmed death-ligand 1 (PD-L1) expression, tumor mutational burden, and microsatellite instability, help predict treatment response, guide treatment selection, and inform clinical trial design in various cancer types. As biomarker testing becomes more widespread and standardized, healthcare providers can identify patients who are most likely to benefit from immuno-oncology drugs, enabling personalized treatment strategies and improving patient outcomes.
Expansion of indications for immuno-oncology drugs is driving innovation in drug development and clinical trial design, with a growing emphasis on combination therapies, rational drug combinations, and adaptive trial designs. Researchers are exploring synergistic interactions between immuno-oncology drugs and other treatment modalities, such as chemotherapy, radiation therapy, targeted therapies, and adoptive cell therapies, to maximize antitumor efficacy and overcome treatment resistance. Additionally, efforts to optimize dosing regimens, treatment schedules, and patient selection criteria are underway to improve the safety and tolerability of immuno-oncology drugs and minimize treatment-related toxicities. As a result, the expansion of indications for immuno-oncology drugs holds promise for transforming the landscape of cancer treatment and improving outcomes for patients with a wide range of malignancies.
Restraints
- High Cost of Treatment
- Limited Efficacy in Some Patients
- Immune-related Adverse Events
-
Complexity of Combination Therapies - The complexity of combination therapies in immuno-oncology presents both challenges and opportunities in cancer treatment. Combination therapies involve the simultaneous or sequential administration of multiple drugs with distinct mechanisms of action to enhance antitumor efficacy, overcome resistance mechanisms, and improve patient outcomes. While combination therapies hold great promise for achieving synergistic effects and maximizing therapeutic benefit, they also pose challenges related to drug interactions, toxicity management, and treatment optimization.
Complexity of combination therapies extends to the management of treatment-related toxicities and adverse events, which may be additive or synergistic when multiple drugs are used concurrently. Immuno-oncology drugs, in particular, can induce immune-related adverse events (irAEs), such as dermatitis, colitis, hepatitis, and pneumonitis, which require prompt recognition and management to minimize morbidity and improve patient outcomes. Healthcare providers must be vigilant in monitoring patients for signs of toxicity, implementing appropriate supportive care measures, and adjusting treatment regimens as needed to optimize safety and tolerability.
Complexity of combination therapies poses challenges in treatment optimization and personalized medicine approaches, particularly in identifying the optimal drug combinations, dosing regimens, and patient selection criteria for individual patients. The selection of combination therapies requires careful consideration of factors such as tumor biology, molecular profiling, treatment history, and patient comorbidities to tailor treatment strategies to the unique characteristics and needs of each patient. Additionally, the design and conduct of clinical trials for combination therapies require innovative trial designs, biomarker-driven approaches, and adaptive strategies to evaluate efficacy, safety, and tolerability in diverse patient populations.
Opportunities
- Expansion into Emerging Markets
- Development of Novel Combination Therapies
- Focus on Biomarker-driven Approaches
- Personalized Treatment Strategies -
Personalized treatment strategies in cancer care represent a paradigm shift towards tailoring therapeutic interventions to the unique characteristics and needs of individual patients. This approach recognizes that cancer is a complex and heterogeneous disease, with variations in tumor biology, genetic mutations, immune microenvironment, and patient-specific factors influencing treatment response and outcomes. By integrating molecular profiling, biomarker testing, and patient-centered care principles, personalized treatment strategies aim to optimize treatment efficacy, minimize adverse effects, and improve patient outcomes across a wide range of cancer types.
Personalized treatment strategies encompass a holistic approach to patient care that considers not only the biological factors but also the psychosocial, cultural, and lifestyle factors that influence health outcomes. Patient-centered care emphasizes shared decision-making, open communication, and collaborative decision-making between patients and healthcare providers, empowering patients to actively participate in their treatment decisions and care plans. By incorporating patient preferences, values, and goals into treatment decisions, personalized treatment strategies promote greater patient satisfaction, adherence to therapy, and overall quality of life.
Data analytics and artificial intelligence are driving innovation in personalized treatment strategies, enabling the development of predictive models, decision support tools, and precision medicine algorithms that optimize treatment selection and dosage optimization. By leveraging big data and predictive analytics, healthcare providers can identify patterns, trends, and risk factors associated with treatment response and adverse events, allowing for more informed clinical decision-making and proactive intervention strategies.
Competitive Landscape Analysis
Key players in Global Immuno-oncology Drugs Market include
- Amgen
- Astra Zeneca
- Bristol-Myers Squib
- Celgene Corporation
- Johnson & Johnson
- Novartis International
- EMD Serono
- Gilead Sciences
- Prometheus Therapeutics & Diagnostics
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Drug Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Region
- Global Immuno-oncology Drugs Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Growing Incidence of Cancer
- Advancements in Immunotherapy
- Rising Demand for Targeted Therapies
- Expansion of Indications for Immuno-oncology Drugs
- Restraints
- High Cost of Treatment
- Limited Efficacy in Some Patients
- Immune-related Adverse Events
- Complexity of Combination Therapies
- Opportunities
- Expansion into Emerging Markets
- Development of Novel Combination Therapies
- Focus on Biomarker-driven Approaches
- Personalized Treatment Strategies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Immuno-oncology Drugs Market, By Treatment Type, 2021 - 2031 (USD Million)
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Oncolytic Virus
- Global Immuno-oncology Drugs Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Immuno-oncology Drugs Market, By Drug Type, 2021 - 2031 (USD Million)
- Immune Checkpoint Inhibitors
- Monoclonal Antibodies
- Cytokine Based Immunotherapy
- Cancer Vaccines
- CAR-T Cell Therapy
- Global Immuno-oncology Drugs Market, By Cancer Type, 2021 - 2031 (USD Million)
- Non-Small Cell Lung Cancer
- Acute Myeloid Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Colorectal Cancer
- Gastric Cancers
- Glioblastoma
- Head & Neck Cancers
- Global Immuno-oncology Drugs Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Immuno-oncology Drugs Market, By Treatment Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Amgen
- Astra Zeneca
- Bristol-Myers Squib
- Celgene Corporation
- Johnson & Johnson
- Novartis International
- EMD Serono
- Gilead Sciences
- Prometheus Therapeutics & Diagnostics
- Company Profiles
- Analyst Views
- Future Outlook of the Market